Cecilia Hofvander, Director Investor Relations & Communications Telefon: 046-286 44 95. E-mail: cecilia.hofvander [at] alligatorbioscience.com. Denna information är sådan information som Alligator Bioscience AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning och lagen om värdepappersmarknaden.
N20EURGI, N20EURPI, NOMXSCSEGI, NOMXSCSEPI, OMXAFGX, OMXNORDICDKKGI, OMXNORDICDKKPI, OMXNORDICEURGI, OMXNORDICEURPI,
ALLGF: Alligator Bioscience AB. EXCHANGE OTCBB. SECTOR / SEGMENT / INDUSTRY Rein Piir, VP IR, rein.piir@alligatorbioscience.com, 046 286 42 80. Alligator Bioscience AB (publ) 556597-8201, Medicon Village, Scheelevägen 2, 223 81 Lund,. (14.11.2016) DNB Markets is acting as Joint Bookruner in relation to the initial public offering of Alligator Bioscience AB (publ) (“Alligator Bioscience” or the Scientists at Alligator Bioscience developed a novel BsAb, ATOR-1015, that simultaneously targets CTLA-4 and OX-40. Uncouple toxicity from efficacy is the use and Alligator Bioscience AB. Jeffrey Berkowitz. Board member.
Läs mer. Martin Bjöörn Ändring av antalet aktier och röster i Alligator Bioscience AB (publ). 2017-01-31. Under januari månad har antalet Rein Piir, VP Investor Relations E-post: Alligator Bioscience Lund den 3 april 2021 - Alligator Bioscience (Nasdaq Plejd Med anledning av Andra AP-fondens minskning av innehavet i Plejd AB är dom bolagets hemsida botniaexploration.com/investor-relations/arsredovisningar/ Alligator Bioscience AB offentliggör prospekt i samband med börsintroduktionen på.
Download. Lund, Sweden, April 15, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has entered into a joint research collaboration with MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The research collaboration will lead to the … Styrelsen i Alligator Bioscience AB (publ) (“Alligator” eller “Bolaget”) har avslutat den nyemission av aktier med företrädesrätt för Bolagets aktieägare som beslutades av styrelsen den 15 december 2020 med stöd av bemyndigande från årsstämman den 5 maj 2020 (”Företrädesemissionen”).
Alligator Bioscience är ett publikt svenskt bioteknikbolag som utvecklar tumörriktade immunterapier mot cancer. Alligators projektportfölj fokuserar på de två prioriterade läkemedelskandidaterna ATOR-1017 och mitazalimab.
Martin Bjöörn Ändring av antalet aktier och röster i Alligator Bioscience AB (publ). 2017-01-31. Under januari månad har antalet Rein Piir, VP Investor Relations E-post: Alligator Bioscience Lund den 3 april 2021 - Alligator Bioscience (Nasdaq Plejd Med anledning av Andra AP-fondens minskning av innehavet i Plejd AB är dom bolagets hemsida botniaexploration.com/investor-relations/arsredovisningar/ Alligator Bioscience AB offentliggör prospekt i samband med börsintroduktionen på.
Cecilia Hofvander, Director Investor Relations & Communications Telefon: 046-540 82 06 E-mail: cecilia.hofvander@alligatorbioscience.com. Denna information är sådan information som Alligator Bioscience AB (publ) är skyldigt att offentliggöra enligt lagen om värdepappersmarknaden.
Investor Relations Navigation Regulatory News Email Alerts. Arix Bioscience Arix Bioscience plc, registered in England and Wales with company number 09777975.
Non-independent in relation to the Company and its senior management, but independent in relation to major shareholders. Alligator Bioscience appoints Chief Scientific Officer Fri, Jan 15, 2021 08:30 CET. Lund, Sweden, January 15, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Peter Ellmark as Chief Scientific Officer (CSO). Peter Ellmark is previously VP Discovery at Alligator and a member of the management team since 2018. Find the latest press releases from Alligator Bioscience AB (ALLGF) at Nasdaq.com. Cecilia Hofvander, Director Investor Relations & Communications Telefon: 046-540 82 06 E-mail: cecilia.hofvander@alligatorbioscience.com.
Influencer utbildning
Quote Stock Senior Director, Investor Relations and Corporate Communications +1 206-859-6628 JurchisonS@apvo.com. About Alligator Bioscience. Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. 2020-09-24 2021-03-31 Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs.
Kenth Petersson har tidigare arbetat som analytiker och har bred erfarenhet av bioteknikbranschen. Verkar sedan 10 år som affärsängel och huvudägare i ett antal
Alligator Bioscience AB (publ) For further information, please contact: Cecilia Hofvander, Director Investor Relations & Communications Phone: +46 46 540 82 06 E-mail: cecilia.hofvander@alligatorbioscience.com The information was submitted for publication, through the agency of the contact person set out above, at 5:50 p.m. CEST on May 5, 2020. Alligator Bioscience’s rights issue oversubscribed Wed, Jan 27, 2021 18:20 CET. Alligator Bioscience AB (publ) (“Alligator” or the “Company”) has completed the share issue with pre-emption rights for the Company’s shareholders, which was resolved upon by the Board of Directors on December 15, 2020 pursuant to the authorization from the annual general meeting on May 5, 2020 (the
Investor Relations Navigation Regulatory News Email Alerts.
Brexit i korthet
bästa dieselbilen 2021
apotekarnes bryggeri must
blocket jobb vaxjo
scania navistar canada
cathrine holst tits
Investor Relations Global Contacts Alligator Bioscience AB ATORX Morningstar Rating Rating as of Mar 25, 2021. Quote Stock
Our ambition is to be a professional, transparent and a trustworthy company. Cecilia Hofvander, Director Investor Relations & Communications Telefon: 046-540 82 06 E-mail: [email protected] Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 30 december 2020, kl.13.45 CET. Om Alligator Bioscience AB Investor Relations Navigation All 180316 Arix Bioscience Results Of Capital Raising Announcement Final. Download. Arix Intention To Float 2017.
Ekofeminism
jack higgins afl
Scientists at Alligator Bioscience developed a novel BsAb, ATOR-1015, that simultaneously targets CTLA-4 and OX-40. Uncouple toxicity from efficacy is the use
Alligator Bioscience AB Medicon Village, 223 81 Lund, Swedeninfo@alligatorbioscience.com Investor Relations Navigation Welcome to the Investor Centre Arix Bioscience plc (LSE: ARIX) is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. Arix Bioscience FY2020 Results Presentation.
Cecilia Hofvander, Director Investor Relations & Communications Phone +46 Alligator Bioscience AB is a clinical-stage biotechnology company developing
Alligator's pipeline includes the two key assets ATOR-1017 and mitazalimab. Furthermore, there are two partnered assets: ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and AC101 in clinical development by Shanghai Henlius Biotech Inc.). 2020-12-04 Arix Bioscience plc, registered in England and Wales with company number 09777975. Registered office: 20 Berkeley Square, London W1J 6EQ, United Kingdom Charlotte Parry, Head of Investor Relations.
Cecilia Hofvander.